INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Myriad Genetics, Inc.

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Myriad Genetics, Inc. (“Myriad Genetics” or “the Company”) (NASDAQGS:MYGN) concerning possible violations of federal securities laws.

On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.” The subpoena requests documents related to Myriad Genetic’s “billing to government-funded healthcare programs for the Company’s hereditary cancer testing” from 2014 through the receipt of the subpoena. To obtain additional information, go to:

http://www.zlkdocs.com/MYGN-Info-Request-Form-6537

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.